- 1、本文档共88页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
课件:CR治疗在心力衰竭中的应用李琼.ppt
* * * * By examining the Kaplan-Meier survival curves, we note that the ICD benefit began after approximately one year. Importantly, as demonstrated by the widening of the curves over time, the ICD benefit appears to increase over time. In an important recent analysis, Dr. Moss announced that there was a 40% cumulative probability of appropriate ICD therapy (ATP or shock) for VT or VF during the 4-year follow-up after ICD implantation. This finding clearly shows the improving cost-effectiveness of ICD therapy with longer follow-up periods.[i] [i] Moss, Arthur. MADIT I and MADIT II. Journal of Cardiovascular Electrophysiology. Vol. 14, No. 9, September 2003 * * Main purpose: Set up discussion for next slide. Key messages: Despite the significant contributions of ACE inhibitors and beta blockers to help heart failure patients live longer, the annual mortality of heart failure patients remains high. As previously shown, moderate to severe heart failure patients with a wide QRS are at higher risk. Cardiac resynchronization and ICD therapies can help this higher risk group live longer Additional information: SOLVD-T was a landmark trial reported in 1991 that showed ACE inhibitors reduced mortality in symptomatic heart failure patients. The MERIT-HF (metroprolol study in Europe and North America) and the CIBIS II (bucindilol in Europe) studies reported in 1999, demonstrated that the addition of beta blockade to conventional treatment, including ACE-inhibitors, further improved survival. The results from these trials are consistent with those reported from the US cardvedilol trial. As reported in the same review paper, if one extracts NYHA III/IV patients from the combined CIBIS II, MERIT-HF and US carvedilol trials, 1- year mortality in the control and treatment groups are 15.15 and 9.5% respectively. * This figure presents sequential changes of left ventricular ejection fraction (A), exercise capacity (functional capacity score) (B), and changes
您可能关注的文档
- 课件:高钾血症对心肌的影响及治疗.ppt
- 课件:言语语言障碍概论.ppt
- 课件:抗雄激素类药物要点.ppt
- 课件:乳腺癌病例分析.pptx
- 课件:疤痕的康复治疗.ppt
- 课件:乳腺癌最新讲座.pptx
- 课件:与乳腺癌的斗争开始了.pptx
- 课件:11基因治疗.ppt
- 课件:关节病的治疗.ppt
- 课件:中医诊疗方案.ppt
- 中国国家标准 GB/T 4706.93-2024家用和类似用途电器的安全 第93部分:商业用湿式和干式真空吸尘器,包括动力刷的特殊要求.pdf
- 《GB/T 4706.93-2024家用和类似用途电器的安全 第93部分:商业用湿式和干式真空吸尘器,包括动力刷的特殊要求》.pdf
- 中国国家标准 GB/T 4706.32-2024家用和类似用途电器的安全 第32部分:热泵、空调器和除湿机的特殊要求.pdf
- GB/T 4706.32-2024家用和类似用途电器的安全 第32部分:热泵、空调器和除湿机的特殊要求.pdf
- 《GB/T 4706.32-2024家用和类似用途电器的安全 第32部分:热泵、空调器和除湿机的特殊要求》.pdf
- GB 2099.7-2024家用和类似用途延长线插座 安全技术规范.pdf
- 中国国家标准 GB 2099.7-2024家用和类似用途延长线插座 安全技术规范.pdf
- 《GB 2099.7-2024家用和类似用途延长线插座 安全技术规范》.pdf
- GB/T 4706.100-2024家用和类似用途电器的安全 第100部分:多功能淋浴房的特殊要求.pdf
- 中国国家标准 GB/T 4706.100-2024家用和类似用途电器的安全 第100部分:多功能淋浴房的特殊要求.pdf
文档评论(0)